Symrise AG Announces Divestment of Terpenes Business and Impairments

Symrise AG has revealed plans to divest its terpenes business, currently in advanced talks with potential buyers. This strategic move involves a structured bidding process, leading to a notable non-cash impairment charge of approximately EUR 145 million in Q4 of 2025. This decision impacts the company's EBIT negatively.

Additionally, Symrise AG faces a non-cash impairment related to its investment in Swedencare AB. Preliminary calculations indicate a charge of EUR 150 million for Q4 of 2025. This adjustment results in a material deviation from 2025 financial expectations, affecting EBITDA adversely.

These impairments do not influence Symrise AG's liquidity or daily operations and will be addressed in the company's earnings report.